NCT02781857Completed
Mass Spectral Fingerprinting in Lung Cancer
Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 309 (actual)
- First submitted
- 26 Apr 2016
- Start date
- May 2016
- Primary completion date
- 6 Mar 2024
- Lead sponsor
- University of Zurich
- Diseases
- Lung cancer
- NCT number
- NCT02781857
What you commit to
- Study type: Observational
- Participants enrolled: 309
- From May 2016 to the primary completion date, 6 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in group A and B, presence of any active malignant disease in group C (based on personal information).
- Acute inflammatory disease (e.g. common cold) within the last 4 weeks.
- Any other acute lung disease which affects breath measurements
- Acute or chronic hepatic disease.
- Renal failure or renal replacement therapy.
Who the study is looking for
- Confirmed lung cancer based on cytological or histological analysis.
- Group A: any type of lung cancer eligible for surgical resection (up to TNM stage IIIa).
- Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not amenable for surgical resection.
- Group C: matched controls.
- Age between 18 and 85 years at study entry
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich, Division of Pneumology Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
Related publications
- Real-time breath metabolomic profiling reveals a volatile signature associated with lung cancer.Biomed Pharmacother · 2026 · PMID 42561601
This page is information, not medical advice. Discuss any trial with your doctor.